ArticleCell2019
Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment.
Open access · hybridAbstract read
In one paragraph
Article in Cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.
0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed
16.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 167 citations in OpenAlex.
- Epithelial-mesenchymal transition in carcinoma: navigating phenotypic states to target resistance and metastasis.Cancer metastasis reviews · 2026Review
- Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Myosin VI drives breast cancer progression via SP1/CA9-mediated acidic tumor microenvironment remodeling and subsequent M2 macrophage polarization.Journal for immunotherapy of cancer · 2026Article
- Implications of Rho GTPase signaling in cancer immunotherapy.Biochemical Society transactions · 2026Review
- NGFR induces melanoma invasion and immunotherapy resistance through myosin light chain 2 modulation.The EMBO journal · 2026Article
- Pan-cancer analysis reveals Rho kinase addiction as a vulnerability of de-differentiated cancer cells.iScience · 2026Article
- Induced chromosomal instability in triple negative breast cancer cells promotes M2-like polarization of macrophages.Scientific reports · 2026Article
- Amoeboid cancer cells at a glance.Journal of cell science · 2026Review
- RIPK4 function interferes with melanoma cell adhesion and metastasis.Molecular oncology · 2026Article
- Pathogenic role and therapeutic targets of nuclear factor-κB signaling pathway in cancer (Review).Oncology letters · 2025Review
- Cellular elasticity drives mechano-adaptation against fluid shear stress.Journal of cell science · 2025Article
- An overview of mechanical microenvironment and mechanotransduction in intervertebral disc degeneration.Experimental & molecular medicine · 2025Review
- MLC2: Physiological Functions and Potential Roles in Tumorigenesis.Cell biochemistry and biophysics · 2025Review
- Article
- A CD24BMC biology · 2025Article
- Reg2ST: recognizing potential patterns from gene expression for spatial transcriptomics prediction.Briefings in bioinformatics · 2025Article
- Bioinformatic prediction of key genes involved in pro-chondrogenic effect of fragmentated cartilage transplantation.Scientific reports · 2025Article
- Extracellular matrix stiffness in endometrial cancer: driving progression and modulating treatment sensitivity via the ROCK1/YAP1 axis.Cell death & disease · 2025Article
- High Copy Number Variations Correlate with a Pro-Tumoral Microenvironment and Worse Prognosis in Acral Lentiginous Melanoma.International journal of molecular sciences · 2025Article
- A Comprehensive Analysis of Epoxide Hydrolase 2 (EPHX2) in Pan-Cancer.Cancer reports (Hoboken, N.J.) · 2025Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 8 institutions in 3 countries.
Mirella GeorgouliRandall Centre for Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, King's College London, London SE1 1UL, UK.
Cecilia HerraizRandall Centre for Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, King's College London, London SE1 1UL, UK.
Eva Crosas-MolistBarts Cancer Institute, John Vane Science Building, Charterhouse Square, Queen Mary University of London, London EC1M 6BQ, UK; Randall Centre for Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, King's College London, London SE1 1UL, UK.
Bruce FanshaweRandall Centre for Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, King's College London, London SE1 1UL, UK; Department of Imaging Chemistry and Biology, Division of Imaging Sciences and Biomedical Engineering, St. Thomas Hospital, King's College London, London SE1 7EH, UK.
Oscar MaiquesBarts Cancer Institute, John Vane Science Building, Charterhouse Square, Queen Mary University of London, London EC1M 6BQ, UK; Randall Centre for Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, King's College London, London SE1 1UL, UK.
Anna PerdrixBarts Cancer Institute, John Vane Science Building, Charterhouse Square, Queen Mary University of London, London EC1M 6BQ, UK; Randall Centre for Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, King's College London, London SE1 1UL, UK; Tumour-Stroma Interactions in Cancer Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Pahini PandyaRandall Centre for Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, King's College London, London SE1 1UL, UK.
Irene Rodriguez-HernandezBarts Cancer Institute, John Vane Science Building, Charterhouse Square, Queen Mary University of London, London EC1M 6BQ, UK; Randall Centre for Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, King's College London, London SE1 1UL, UK.
Kristina M IlievaSt John's Institute of Dermatology, King's College London and National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas' Hospitals and King's College London, London SE1 9RT, UK.
Gaia CantelliRandall Centre for Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, King's College London, London SE1 1UL, UK.
Panagiotis KaragiannisSt John's Institute of Dermatology, King's College London and National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas' Hospitals and King's College London, London SE1 9RT, UK; Department of Oncology, Haematology and Stem Cell Transplantation, University Hospital of Hamburg Eppendorf, Hamburg 20246, Germany.
Silvia MeleSt John's Institute of Dermatology, King's College London and National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas' Hospitals and King's College London, London SE1 9RT, UK.
Hoyin LamRandall Centre for Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, King's College London, London SE1 1UL, UK.
Debra H JosephsSt John's Institute of Dermatology, King's College London and National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas' Hospitals and King's College London, London SE1 9RT, UK; School of Cancer and Pharmaceutical Sciences, Guy's Hospital, King's College London, London SE1 9RT, UK.
Xavier Matias-GuiuDepartments of Pathology Hospital U Arnau de Vilanova and Hospital U de Bellvitge, IRBLLEIDA, IDIBELL, University of Lleida, CIBERONC, Lleida, Spain.
Rosa M MartiDepartment of Dermatology, Hospital U Arnau de Vilanova, IRBLLEIDA, University of Lleida, CIBERONC, Lleida, Spain.
Frank O NestleSt John's Institute of Dermatology, King's College London and National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas' Hospitals and King's College London, London SE1 9RT, UK.
Jose L OrgazBarts Cancer Institute, John Vane Science Building, Charterhouse Square, Queen Mary University of London, London EC1M 6BQ, UK; Randall Centre for Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, King's College London, London SE1 1UL, UK.
Ilaria MalanchiTumour-Stroma Interactions in Cancer Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Gilbert O FruhwirthDepartment of Imaging Chemistry and Biology, Division of Imaging Sciences and Biomedical Engineering, St. Thomas Hospital, King's College London, London SE1 7EH, UK.
Sophia N KaragiannisSt John's Institute of Dermatology, King's College London and National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas' Hospitals and King's College London, London SE1 9RT, UK.
Victoria Sanz-MorenoBarts Cancer Institute, John Vane Science Building, Charterhouse Square, Queen Mary University of London, London EC1M 6BQ, UK; Randall Centre for Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, King's College London, London SE1 1UL, UK. Electronic address: v.sanz-moreno@qmul.ac.uk.
King's College London · GBQueen Mary University of London · GBNational Institute for Health Research · GBHospital Universitari Arnau de Vilanova · ESNIHR Biomedical Research Centre at The Royal Marsden and the ICRThe Francis Crick Institute · GBUniversitat de Lleida · ESUniversity Medical Center Hamburg-Eppendorf · DE
Funding
Cancer Research UK 12065Cancer Research UK 14257Cancer Research UK 21153Cancer Research UK 24478Cancer Research UK C10355/A15587Cancer Research UK C30122/A11527Cancer Research UK C30122/A15774Cancer Research UK C33043/A24478Cancer Research UK C48390/A21153Cancer Research UK FC001112Department of Health IS-BRC-1215-20006Medical Research Council FC001112Medical Research Council MR/L023091/1Wellcome Trust FC001112Worldwide Cancer Research 16-1135
Abstract
ROCK-Myosin II drives fast rounded-amoeboid migration in cancer cells during metastatic dissemination. Analysis of human melanoma biopsies revealed that amoeboid melanoma cells with high Myosin II activity are predominant in the invasive fronts of primary tumors in proximity to CD206
Indexed as
AdultAgedAged, 80 and overAnimalsCell AdhesionCell Line, TumorCell MovementCytoskeletal ProteinsFemaleHumansInterleukin-1alphaMaleMelanomaMiceMice, Inbred C57BLMice, SCIDCytoskeletal ProteinsInterleukin-1alphaMyosin Type IINF-kappa BmacrophagesNF-κBprotein secretionROCK-Myosin IIrounded-amoeboid melanoma cellstumor invasive front
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.